30160.0000 -5.00 (-0.02%)
NSE May 12, 2025 14:36 PM
Volume: 4,080
 

30160.00
-0.02%
ICICI Securities Limited
Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.
BOB Capital Markets Ltd. released a Buy report for Abbott India Ltd. with a price target of 35292.0 on 29 Apr, 2025.
More from Abbott India Ltd.
Recommended